[17][18] On the same day the company announced it would partner with Hanmi Pharmaceutical to develop and commercialise HM61713, a third generation treatment for EGFR mutation-positive lung cancer.

[21] In July 2016, the company sold the commercialisation rights to BI 655066 (Risankizumab), to AbbVie for $595 million upfront as well as undisclosed milestone payments and royalties.

[26] In September of the same year, Amgen announced it would purchase the rights to Boehringer Ingelheims Phase I bispecific T-cell engager compound (BI 836909, now AMG 420) for use in the treatment of multiple myeloma.

[28][29] In October 2016 the company sold its US pet vaccines business and a manufacturing plant for $885 million, to Eli Lilly's Elanco Animal Health division.

[35] In July, subsidiary company Boehringer Ingelheim Pharmaceuticals, Inc. announced it had acquired Amal Therapeutics SA, boostings the business' focus on cancer immunotherapy and vaccine treatments.

[38] In July, the company announced it would acquire Global Stem cell Technology (GST), boosting its animal health business.

[41][42] In June 2020, Boehringer and G1 Therapeutics announced a co-promotion agreement for trilaciclib (Cosela), a CDK4/6 inhibitor designed to prevent chemotherapy-induced myelosuppression.

[43] The agreement targets small cell lung cancer, will initially run for three years, and covers the United States and Puerto Rico.

[52][53] The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.

[56] Prescription Medicines: Consumer Health Care (sold to Sanofi): Animal Health: Also in companion animal portfolio: Purevax feline vaccines, Recombitek canine vaccine, Imrab rabies vaccine, NexGard (afoxolaner), NexGard Spectra (afoxolaner/milbemycin oxime), NexGard Combo (esafoxolaner/eprinomectin/praziquantel), Heartgard-30 Plus (ivermectin/pyrantel pamoate), Immiticide (melarsomine), Senvelgo (velagliflozin) Boehringer Ingelheim's product pipeline targets lung disease, cancer, and hepatitis C.[57] In October 2012 Boehringer Ingelheim settled a "qui tam" (whistleblower) case with the U.S. government for $95 million alleging "off-label" marketing of the drugs Aggrenox, Atrovent, Combivent, and Micardis for uses that weren't approved by the US Food and Drug Administration and were not covered by federal health care programs.

[59] In August 2012, Pradaxa claims filed in the federal court were consolidated in a multi-district litigation in the Southern District of Illinois before Chief Judge David R. Herndon.

[60] In October 2023 Boehringer Ingelheim was ordered to pay a 10 million Euro fine for illegal price fixing that had gone on globally over a period of nearly fifteen years.

[64] As a private company, Boehringer Ingelheim (BI) is not required to disclose detailed financial information publicly; the owners have considered an IPO and ruled it out.

[65] In 2006, the Chairman of the Shareholders’ Committee Dr Heribert Johann retired and Christian Boehringer took over the position as chairperson of the board of directors.